NANOLEK and NPK kombiotekh will release the HPV vaccine

NANOLEK and scientific-production company KOMBIOTEKH announced the partnership on domestic production 4-valent vaccine against human papillomavirus (HPV) 4 types (6, 11, 16, 18). Investment in the project will amount to about 1.8 billion rubles.

The vaccine will be produced in full cycle production capacities NANOLEK in the Kirov region in full compliance with GMP standards and technical requirements for the production of such vaccines. The vaccine has a high export potential, noted by the parties. To date, the who increased purchases and predicts supply shortages of the vaccine in the future, so the project also involves an export component (planned prequalification of the vaccine according to the who requirements). Until 2027, the who predicts a shortage of the vaccine in up to one third of the demand.

According to the world health organization, cervical cancer is the only cancer that is preventable by primary prevention with HPV vaccination. In Russia, the economic damage from cervical cancer associated with HPV is 50 billion rubles. per year.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]